Session Details
[3BS-01]GENEWIZ™ (Azenta Japan Corp.)
Fri. Dec 5, 2025 1:20 PM - 1:50 PM JST
Fri. Dec 5, 2025 4:20 AM - 4:50 AM UTC
Fri. Dec 5, 2025 4:20 AM - 4:50 AM UTC
Seminar Booth 1 (Pacifico Yokohama Exhibition Hall)
Chairperson：Yasunori Okazaki (GENEWIZ (Azenta Japan Corp.))
GENE to Antibody – High-Precision NGS for Hybridoma Analysis and Recombinant Antibody Production
GENEWIZ offers a one-stop solution for antibody research and development, from antibody sequence acquisition to recombinant antibody (rAb) production. Our hybridoma analysis service utilizes NGS technology to accurately identify variable regions within mixed antibody gene populations. This enables high-sensitivity, high-resolution, and high-throughput profiling of antibody sequences.
In addition, under the “Gene-to-Antibody” concept, we can deliver high-quality recombinant antibodies in as little as three weeks. Projects can be customized to meet specific requirements, and we have extensive experience supporting a wide range of antibody formats. Technical support is provided by our antibody experts, and the service is ideal for confirming the functionality of AI-designed antibody sequences, improving physical properties through antibody engineering, and screening candidate antibodies.
In this seminar, we will present concrete processes and case studies demonstrating how these technologies and services can support antibody discovery through development.
In addition, under the “Gene-to-Antibody” concept, we can deliver high-quality recombinant antibodies in as little as three weeks. Projects can be customized to meet specific requirements, and we have extensive experience supporting a wide range of antibody formats. Technical support is provided by our antibody experts, and the service is ideal for confirming the functionality of AI-designed antibody sequences, improving physical properties through antibody engineering, and screening candidate antibodies.
In this seminar, we will present concrete processes and case studies demonstrating how these technologies and services can support antibody discovery through development.
Introduction
[3BS-01-01]NGS-Based High-Throughput, High-Precision Hybridoma Sequencing
Koichi Akiyama(GENEWIZ (Azenta Japan Corp.))
[3BS-01-02]Cutting-Edge End-to-End Recombinant Antibody Production
Takashi Yabuki(GENEWIZ (Azenta Japan Corp.))